As global markets navigate a tumultuous landscape marked by escalating trade tensions and fluctuating consumer sentiment, the tech sector remains a focal point for investors seeking growth ...

Bristol Myers' Camzyos missed goals in a Phase 3 nHCM trial, showing no significant benefits over placebo but raised no new safety concerns.

Bristol Myers' Camzyos missed goals in a Phase 3 nHCM trial, showing no significant benefits over placebo but raised no new ...

“Participating in the program provides grad students with training and an opportunity to share their research, practice their ...

OmniAb, Inc. will report financial results for the three months ended March 31, 2025 after the close of the U.S. financial markets on Thursday, May 8, 2025, and will hold a conference call that same ...

We're excited to begin this collaboration with Astellas, said Michael Roberts, CEO and Founder of Chromatin Bioscience. We believe the ability to precisely control targeted gene expression is becoming ...

Using electrodes in a fluid form, researchers at Linköping University have developed a battery that can take any shape. This ...

China's Juneyao Airlines reportedly is delaying delivery of a Boeing 787-9 Dreamliner aircraft because of President Trump's ...

Keros Therapeutics is considering whether it needs to find a buyer, while strengthening its stockholder rights as activist ...

Spatial biology first entered the omics scene about a decade ago. Since then, the technology has generated significant buzz ...

Shares in large US and European drugmakers slide, underperforming amid a broad market slump, after President Donald Trump said the US was planning to announce "a major tariff on pharmaceuticals" soon.

Pacific Biosciences is reducing both headcount and spending across its DNA sequencing business, in the face of escalating global tariffs and threats to federal biomedical research grants. | Looking to ...